RxSight, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 48/100
What the filing says
RxSight reported Q3 2026 revenue of $24.6M (down 19% from $30.3M in Q3 2025), driven by 23,128 LAL unit sales. Net loss widened to $(16.2)M ($(0.39)/share) vs. $(9.8)M in Q3 2025. The company received $60M cash from the Alcon collaboration in Q3, bringing total liquidity to $254.7M as of Sept 30, 2026. Gross margin fell to 73.6% from 79.9% due to inventory reserves and higher costs. Leadership additions: Taryn Conway (Chief Commercial Officer) and Frank Shields (EVP Sales). Nine-month 2026 revenue: $89.2M vs. $101.9M in 9M 2025.
Why this rating
Revenue decline 19% YoY signals competitive pressure; losses deepened. $60M cash infusion provides runway but represents ~12% of market cap—moderate near-term relief, not transformational. Alcon collaboration early-stage; immaterial Q3 revenue impact.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.